Navigation Links
Octapharma Announces octagam® 5% Again Available for U.S. Purchase
Date:11/30/2011

HOBOKEN, N.J., Nov. 30, 2011 /PRNewswire/ -- Octapharma USA announced that octagam® [Immune Globulin Intravenous (human) 5% Liquid Preparation] is again available for purchase. The U.S. Food and Drug Administration (FDA) on Nov. 3 approved the U.S. market return of octagam® 5%, a therapy to treat disorders of the immune system.

(Photo: http://photos.prnewswire.com/prnh/20111130/NY14410)

In August 2010, Octapharma initiated a voluntary market withdrawal of octagam® 5% in the U.S. in response to an observed increase in thromboembolic events (TEEs), which occur when a clot or thrombus forms locally in a blood vessel or breaks loose in the blood stream to occlude another vessel. Octapharma has reported that global sales totaled 1.7 million grams of octagam® 5% and octagam® 10%,  [Immune Globulin Intravenous (Human) Liquid Preparation] in the period January 1 through October 30, 2011, an estimated 60,000 treatments, during which there were no reports of TEEs.

"It is a very exciting time for patients throughout the U.S. as they again have access to octagam® 5%, a therapy that has long been valued by the medical comm
'/>"/>

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
5. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
9. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
10. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
11. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... N.J. and NEW YORK , ... and Company) (NYSE: BDX ) are accelerating the ... and glucose sensing technologies through a new collaboration announced today. ... collaborations focused on type 1 diabetes (T1D). Many ... insulin pump – requiring a catheter to be placed in ...
(Date:6/18/2013)... Today, Wall Street Reports announced new research reports ... Management Associates Inc. (NYSE: HMA ), IDEXX Laboratories, ... ISIS ), and Trius Therapeutics Inc. (NASDAQ: TSRX). ... including full price targets, industry analysis and analyst ratings - ... Report On June 7, 2013, Gilead Sciences Inc. ...
(Date:6/18/2013)... June 18, 2013 Remedy Informatics, a ... and life sciences research, today announced it has ... IT Schedule 70 supply contract (GS-35F-367AA, effective May ... innovative IT solutions to government agencies at federal, ... contract, Remedy has placed its products and services ...
Breaking Medicine Technology:JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... treatments for human disease, announced today that Arthur ... executive officer, will present at the Morgan Stanley Global ... 14, 2011 at 9:10 a.m. Eastern Time.  Dr. Sands ...
... Sept. 5, 2011 Reportlinker.com ... research report is available in ... Facial Aesthetics (Botox, Dermal Fillers, ... Competitive Landscape and Market Forecasts ...
Cached Medicine Technology:Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference 2Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9
(Date:6/18/2013)... (PRWEB) June 18, 2013 Biomet ... continue to move forward in a multidistrict litigation in ... LLP reports. According to court records, the litigation’s ... at which time the Court also convened a motions ... issues pertinent to the Biomet hip replacement litigation. ...
(Date:6/18/2013)... Seven-year-old Riley Salz of Encino, California, is ... 40 hours a week of applied behavior analysis (ABA) ... for Autism and Related Disorders (CARD). Riley has been ... experienced remarkable progress, including learning to speak, starting conversations, ... journey through autism is now featured in CARD’s “Mission ...
(Date:6/18/2013)... Recent research has shown that cancer cells have a ... normal cells. Now, scientists at The University of Texas ... provide a new strategy to combat lung cancer. , ... journal PLOS ONE , UT Dallas researchers compared ... normal lung cells taken from the same patient. ...
(Date:6/18/2013)... at Case Western Reserve University,s College of Arts ... made available avatarsvirtual patientsto train speech-language pathologists. ... to evaluate speech-language disorders to practice using an ... because a diagnosis doesn,t have to be made ... studying to become speech-language pathologists have previously relied ...
(Date:6/18/2013)... Belleville, Ill. (PRWEB) June 18, 2013 More ... older are living with HIV/AIDS, according to the Centers for ... don’t know they are infected. In support of National HIV ... Social Security Disability Insurance (SSDI) representation, the CDC ... HIV testing. , The CDC reports about 50,000 new ...
Breaking Medicine News(10 mins):Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3
... boosted hearing in such children , THURSDAY, Feb. ... hearing improvement for children and teens with single-sided deafness, ... 3 percent of children have deafness on one side, ... difficulties and behavioral problems. Traditional external hearing aids are ...
... ... NFL Draft pick would have to find a personal trainer, physical therapist, ... them compete with the best athletes in the world. But Athletes, ... offered an NFL Combine preparation program, and this year Trigger Point Performance ...
... , Scientists at the Johns Hopkins Kimmel Cancer Center ... cancer patients to develop individualized blood tests they believe ... blood tests, believed to be the first of their ... therapy and determine cancer recurrence., "We believe this ...
... It is not unusual to hear people blame their metabolism ... process that shapes how our bodies turn food into energy -- ... fit into your favorite jeans. In fact, differences in ... cells, though the mechanism behind it is unclear. Now new research ...
... patients perform significantly better on tests of cognitive function than ... MRI scans of the patients showed that the fitter MS ... show deterioration as a result of MS, as well as ... that aerobic fitness has a protective effect on parts of ...
... ... Opinion Survey and Special Supplement on Health Care Reform , ... Indianapolis, IN (Vocus) February 18, 2010 -- ... benefits advisory organizations, today announced the opening of the 2010 UBA Employer Opinion ...
Cached Medicine News:Health News:Small Time Company Rolls into the Big League: Trigger Point Performance Therapy Selected to Attend Athletes' Performance NFL Combine Preparation Program 2Health News:Small Time Company Rolls into the Big League: Trigger Point Performance Therapy Selected to Attend Athletes' Performance NFL Combine Preparation Program 3Health News:Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing 2Health News:Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing 3Health News:Chemical tags likely to affect metabolism, cancer development 2Health News:Exercise helps protect brain of multiple sclerosis patients 2Health News:Exercise helps protect brain of multiple sclerosis patients 3Health News:Employers Voice Opinions on Health Care Plans, Gain Insights on Health Care Reform 2Health News:Employers Voice Opinions on Health Care Plans, Gain Insights on Health Care Reform 3
Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
Medicine Products: